Wockhardt Share Price Rises Over 6%, Hits 52-Week High Following Drug Approval

On January 3, 2025, Wockhardt’s share price jumped over 6%, reaching a 52-week high. This surge followed the approval of its new oral antibiotic, Miqnaf® (Nafithromycin), by the Central Drugs Standard Control Organization (CDSCO) as a new treatment for Community-Acquired Bacterial Pneumonia (CABP) in Adults. 

Approval of Miqnaf®: A Game-Changer in Pneumonia Treatment

Miqnaf® has been approved as a treatment for Community-Acquired Bacterial Pneumonia (CABP). It offers a three-day, once-a-day dosage, providing an ultra-short course treatment, including cases caused by multi-drug resistant pathogens.

The approval marks a breakthrough, addressing antibiotic resistance challenges and reducing hospitalization needs. Miqnaf® is set to launch in India in the coming months.

Extensive Research and Development

Wockhardt’s Miqnaf® underwent more than 15 years of rigorous non-clinical and clinical trials across the U.S., Europe, South Africa, and India. It is the first macrolide-based CABP treatment in India in nearly three decades, offering a new option to combat resistant strains of bacteria.

Significance in Combating Antibiotic Resistance

India bears 23% of the global burden of CABP. Current antibiotics like azithromycin and amoxicillin/clavulanate face growing resistance issues. Miqnaf® addresses these gaps by covering a broad spectrum of respiratory pathogens, including those resistant to existing therapies.

Wockhardt’s Legacy in Antibiotic Discovery

Wockhardt has invested 25 years in drug discovery, focusing on antibiotics for multi-drug resistant infections. It boasts 6 products with Qualified Infectious Disease Product (QIDP) status from the U.S. FDA.

The company operates globally with research and manufacturing facilities in India, the U.S., the UK, and Ireland, employing 2,600 people across 27 nationalities.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.